Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 21 |
| Active Pipeline (Recruiting Now) | 5 (4) |
| Completed vs Stopped Early | 13 / 3 (14.3%) |
| Median Closed Actual Enrollment | 288 participants |
| Physical Hospital Site Disclosure | 80.5% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Mayo Clinic Rochester | Rochester, MN | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06545955 | A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With Hi | Phase III | RECRUITING |
| NCT06510374 | Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Ferring Pharmaceuticals Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.